Clinical trials: Oral Malignancy
Non-muscle Invasive Bladder Cancer
A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients
A multi-center, randomized, open-label, parallel-controlled Phase Ⅲ clinical trial to evaluate the clinical safety and efficacy of APL-1202 as a single-agent oral treatment versus intravesical instillation of Epirubicin…
- Trial name
- ASCERTAIN (NCT04736394)
- Testing
- APL-1202, Epirubicin Hydrochloride
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
Medical Oncology
Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
To evaluate the effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of roniciclib in cancer patients. To assess safety and tolerability of roniciclib dosing when administered with and without itraconazole…
- Trial name
- NCT02457351
- Testing
- Roniciclib (BAY 1000394), Itraconazole (Sporanox)
- Where
- 4 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Bayer
Breast Cancer
Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)
Primary Objective: To assess the incidence rate of dose-limiting toxicity and to confirm the recommended dose as well as the maximum tolerated dose of SAR439859 administered as monotherapy to Japanese postmenopausal women with…
- Trial name
- AMEERA-2 (NCT03816839)
- Testing
- Amcenestrant (SAR439859)
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Sanofi
Carcinoma, Transitional Cell
Tesetaxel for Previously Treated Patients With Bladder Cancer
The intravenously administered taxanes, docetaxel and paclitaxel, alone and in combination with other chemotherapy agents are active in patients with advanced and metastatic bladder cancer, and agents of this class are a…
- Trial name
- NCT01215877
- Testing
- Tesetaxel
- Where
- 3 sites in United States, Italy
- Volunteers
- 33 people
- Sponsor
- Genta Incorporated
Mucositis, Pain
Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
This was an open-label, single-dose study to assess the safety, tolerability, and absorption/distribution kinetics of a single 100 µg dose of fentanyl sublingual spray in opioid-tolerant cancer subjects, with or without oral…
- Conditions
- Mucositis, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00956254
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- INSYS Therapeutics Inc
Neoplasms
A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas
This is a phase I, open-label, multiple dose, dose escalation study to assess the safety, tolerability and pharmacokinetics of Aneustat™ (OMN54), a novel therapy, administered orally in patients with advanced cancer and lymphomas.
- Trial name
- NCT01555242
- Testing
- Aneustat (OMN54)
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Omnitura Therapeutics, Inc.
Squamous Cell Carcinoma of the Oral Cavity
Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
The primary objective of this open label Phase Ib/II trial is to evaluate the clinical and pharmacological activity of IPH2201 as a single-agent in treatment-naïve pre-operative patients with operable Squamous Cell Carcinoma of…
- Trial name
- NCT02331875
- Testing
- IPH2201, Standard Surgery, Postsurgical Adjuvant Therapy
- Where
- 3 sites in Germany, Spain
- Volunteers
- 3 people
- Sponsor
- Innate Pharma
Advanced Solid Tumor
A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors
In this study, BEZ235 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists.
- Trial name
- NCT01195376
- Testing
- BEZ235
- Where
- 2 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Medical Oncology
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
Determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), and/or recommended Phase II dose (RP2D) of oral BAY 1143269 given alone or in combination with intravenous (IV) docetaxel in subjects with…
- Trial name
- NCT02439346
- Testing
- BAY1143269 tablet
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Bayer
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of TY-1091 in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms
- Trial name
- NCT05675605
- Testing
- TY-1091
- Where
- China
- Volunteers
- 248 people
- Sponsor
- TYK Medicines, Inc
Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN)
TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to learn if an experimental, personalized cancer vaccine called TMV vaccine is safe and to find the best dose to study in future trials.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local
- Trial name
- NCT07898124
- Testing
- TMV Vaccine, Toripalimab-tpzi
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Metaclipse Therapeutics Corporation
Malignant Melanoma, Neoplasms
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
This open-label, multi-center, three-period, one sequence study will investigate the effect of ketoconazole on the pharmacokinetics of vemurafenib in patients with unresectable BRAFV600-mutation positive metastatic melanoma or…
- Trial name
- NCT01765556
- Testing
- ketoconazole, vemurafenib
- Sponsor
- Hoffmann-La Roche
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of palonosetron compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug), both given with oral dexamethasone.
- Trial name
- NCT01363479
- Testing
- Oral palonosetron, I.V. palonosetron, Dexamethasone
- Where
- 79 sites in United States, Argentina and 10 more
- Volunteers
- 743 people
- Sponsor
- Helsinn Healthcare SA
Solid Tumors
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.
- Trial name
- NCT00750841
- Testing
- cediranib
- Where
- 6 sites in Canada, United Kingdom
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Healthy
A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers
This is an open label, randomized, single dose, one cohort, two sequence, two period crossover study in healthy subjects. The primary objective of the study is to evaluate the effect of a single oral dose of aprepitant on the…
- Trial name
- NCT02058277
- Testing
- bosutinib or bosutinib + aprepitant
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Oncology, MEK Mutation
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway…
- Conditions
- Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation
- Trial name
- NST-628 (NCT06326411)
- Testing
- NST-628
- Where
- 23 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- Nested Therapeutics, Inc
Nausea and Vomiting, Chemotherapy-Induced
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
This is a Phase III trial designed to demonstrate that casopitant when added to dexamethasone and ondansetron is more effective in the prevention of vomiting then dexamethasone and ondansetron alone, in patients who receive a…
- Trial name
- NCT00431236
- Testing
- Oral Casopitant (GW679769), IV Casopitant (GW679769), IV ondansetron hydrochloride
- Where
- 80 sites in Argentina, Belgium and 20 more
- Volunteers
- 810 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Leukemia
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma
- Trial name
- NCT00621244
- Testing
- LBH589
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC
Iressa as Second Line Therapy in Advanced NSCLC-Asia
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational…
- Trial name
- ISTANA (NCT00478049)
- Testing
- Gefitinib, Docetaxel
- Where
- 4 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Pain
An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain
The purpose of this study is to compare the safety and efficacy of Oral Osmotic Therapeutic System (OROS) hydromorphone hydrochloride (HCl) with controlled-release oxycodone HCl in participants with cancer-related pain.
- Trial name
- NCT01205126
- Testing
- Hydromorphone HCl, Oxycodone HCl CR
- Where
- 12 sites in China
- Volunteers
- 260 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.